Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 355.89M P/E - EPS this Y 43.20% Ern Qtrly Grth -
Income -29.25M Forward P/E - EPS next Y -135.10% 50D Avg Chg 1.00%
Sales 2M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -3.00%
Recommedations 2.00 Quick Ratio 29.05 Shares Outstanding 30.67M 52W Low Chg 9.00%
Insider Own 14.11% ROA -21.54% Shares Float 16.20M Beta -
Inst Own 70.10% ROE -29.32% Shares Shorted/Prior 2.07M/1.81M Price 16.05
Gross Margin 100.00% Profit Margin - Avg. Volume 89,276 Target Price 32.60
Oper. Margin -1,813.75% Earnings Date - Volume 57,395 Change 0.25%
About Sagimet Biosciences Inc. - Seri

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc. - Seri News
11/26/24 Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/18/24 Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
11/18/24 Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
11/14/24 Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
07:30 AM Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
10/29/24 Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
10/16/24 Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
10/11/24 Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
10/01/24 Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
09/30/24 Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/12/24 Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
09/04/24 Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
08/14/24 Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
08/01/24 Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
06/21/24 Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
06/10/24 Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
06/06/24 Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
05/16/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
05/15/24 Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
07:00 AM Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
SGMT Chatroom

User Image Effe839 Posted - 41 minutes ago

$SGMT That -9% deep was a sweet buy 🤭

User Image valueforme Posted - 17 hours ago

$SGMT C'mon Thierry, time to show your kung fu here

User Image Stocks4thought Posted - 21 hours ago

$SGMT Crooks running the tables. Nothing more- computers vs humans or retail.

User Image ElonMustLoveYou Posted - 1 day ago

$SGMT Oppenheimer sets $30 target on Sagimet Biosciences shares

User Image valueforme Posted - 1 day ago

$SGMT Jay Olson, Oppenheimer Very thoughtful guy. Here is an example of his obesity names coverage - https://www.biotechtv.com/post/jay-olson-august-8-2024 And he called VKTX last year. So, $30 from Jay is pretty nice

User Image cats44ever Posted - 1 day ago

$SGMT Thanks for posting Quantumup; don't know why they came out with the research note after hours.... much greater effect before market.

User Image Quantumup Posted - 1 day ago

Oppenheimer🏁 $SGMT Outperform/$30. $MDGL $IVA $VKTX $ALGS ETNB AKRO LLY NVO Oppenheimer said in its research note: We initiate coverage of Sagimet Biosciences Inc. ( $SGMT ) with an Outperform rating and $30 PT. We see an underappreciated opportunity for lead asset denifanstat, a first-in-class fatty acid synthase (FASN) inhibitor, in metabolic dysfunction-associated steatohepatitis (#MASH) expected to reach ~$15B in market potential. We anticipate a near-term catalyst upon $SGMT raising ~$200M additional capital for ongoing Ph3 registrational trials by leveraging denifanstat's competitive profile based on Ph2b data. We see $SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve. Our coverage of the MASH and obesity markets informs our optimistic view. Separately, the Ascletis partnership could provide additional value creation with Ph3 readouts for denifanstat in glioblastoma (GBM) expected in 1H25 and acne in 2H25.

User Image cats44ever Posted - 1 day ago

$SGMT Don't want anyone to misread me; I'm extremely positive on this company & expect great results from the Ascletis Acne trial ending in 2Q 2025. All of the Denifanstat cancer trials were longshots... the GBM Brain Cancer, Small Cell Lung Cancer, Prostate Cancer, Breast Cancer & Colon Cancer trials. Still, the possibility exists/existed for some kind of success & breakthrough that would turn Deni into a wonderdrug with huge price appreciation... still hoping for that with the Acne trial, but have to be patient for the next 6 months. For now, I'll restrict myself to shorting Jan 5 puts for short term gratification (!).

User Image Dark_Horse_Investments Posted - 1 day ago

$SGMT I personally assign zero value for sgmt on this trial. I am in on this for MASH and would say that the intrinsic value is well ahead of $4.72 - i venture to say that the company on the low end is worth $300 million. With this in mind, what is your theory on the oncology trial. I cannot find any updates... THX in advance

User Image cats44ever Posted - 1 day ago

$SGMT We were told this summer to expect interim results in Q4 2024... but now (stated at the Piper conference), it's 'sometime in 2025'. The clinical trial site shows they ended enrollment as of 10/31/24, with only 136 out of the expected 180 patients that were supposed to participate in the trial; study end pushed back from 12/24 to 6/25. This despite a pdf 11/8/24 presentation from Ascletis stating that there would be 180 trial subjects & interim results due out by year end, but now... that presentation has been pulled (or is no longer available in English).

User Image cats44ever Posted - 1 day ago

$SGMT $SGMT Something not quite right with the Ascletis GBM cancer trial.

User Image kthart Posted - 1 day ago

$SGMT only down 10% in the first three hours? Sheeet might as well drop it to $2.2 in the next couple weeks if goldmuck sux is still shorting

User Image Peterson28 Posted - 1 day ago

$SGMT Going to close the 4.77 gap on daily. Then go back up to 6.

User Image valueforme Posted - 1 day ago

$SGMT Stop loss fishing

User Image rational1 Posted - 2 days ago

$sgmt and there it is. MM's dropped it from $5.50 this a.m. to fill the gap on less than 100K shares. Nasdaq is crooked & I am close to swearing off any further investment dollars in their rigged system. Must remember to sell on the next positive news bounce.

User Image rational1 Posted - 3 days ago

$SGMT MM push is on to fill the small gap @ $5.17 from last week. Market is rigged in case you had any doubts.

User Image nastento Posted - 3 days ago

$SGMT love how they're getting pressure from everyone about financing lol I'm sure it complicated

User Image kthart Posted - 3 days ago

$SGMT Happel says they are extremely fortunate to have so much interest, everything on the table, minimal dilution blah blah blah...anyone curious what they come up with? lol

User Image valueforme Posted - 3 days ago

$SGMT The most important part of today's conference. Everything is on the table and dilution minimization is key

User Image valueforme Posted - 4 days ago

$SGMT I was asked in the comments which funding scenario is the worst, and my answer is not surprisingly " public offering" Let me share what my dream scenario is. It is called a "biohaven-like" asset sale. How it works is described here - https://www.insidearbitrage.com/2024/01/inhibrx-acquisition-structured-like-the-biohaven-deal-merger-arbitrage-mondays/ Basically, in my dream scenario - MASH interested acquirer buys Sagimet with Denifanstat, but another FASN molecule TVB-3567 goes to "new Sagimet" with all the current cash on hand that Sagimet has now. This cash is enough to fund TVB-3567 in acne to approval, Dave said that at UBS conference - new Sagimet is a traded public company - we get let's say $25 per share as a distribution for old Sagimet+ 0.8 share of new Sagimet for every share of old Sagimet.

User Image valueforme Posted - 4 days ago

$SGMT Piper Sandler conft tomorrow, do not forget. Nothing interests me at this point but financing. Announce the financing deal tomorrow morning, Dave, and then talk through the terms during the conference https://ir.sagimet.com/events/event-details/piper-sandler-36th-annual-healthcare-conference

User Image valueforme Posted - 4 days ago

$SGMT I think we'll see 2 transactions announced the same day: - selling synthetic royalty for 100M (e.g. HealthCare Royalty Partners) - classic debt for 100M (e.g. SLR Life Science) Recent precedent of such funding from 2 different sources announced the same day - GERN https://www.businesswire.com/news/home/20241107070171/en/Geron-Corporation-Announces-Up-to-375-Million-in-Funding-with-Royalty-Pharma-and-Pharmakon-Advisors

User Image valueforme Posted - 4 days ago

$SGMT In the meantime, synthetic royalty (royalties for non-approved drugs) deals are growing like crazy recently. Since November 1, 2024: SNDX, GERN, KALV, ASND

User Image valueforme Posted - 4 days ago

$SGMT This is another way how financing of phase 3 might end up - classic debt or convertible debt

User Image valueforme Posted - 4 days ago

$SGMT

User Image nastento Posted - 4 days ago

$SGMT

User Image Tjcmd Posted - 11/29/24

$SGMT Has the funding been decided on?

User Image Stocks4thought Posted - 11/29/24

$SGMT $5.84 and we will start the journey over $6 again@@# ot $ALT $S

User Image Stocks4thought Posted - 11/29/24

$SGMT El Chopostick- aligning perfect with $6 and every body likes six................ ot $VKTX $ALT $BWAY $

User Image Stocks4thought Posted - 11/29/24

$SGMT $7 soom ot $SLNO $VKTX $ALT $BWAY deeply discounted because of funding event---------not gonna discount- and more commissions for IB's on higher pps. See ya

Analyst Ratings
HC Wainwright & Co. Buy Oct 2, 24
JMP Securities Market Outperform Aug 15, 24
HC Wainwright & Co. Buy Aug 15, 24
Goldman Sachs Neutral Jul 1, 24
HC Wainwright & Co. Buy Jun 14, 24
JMP Securities Market Outperform Jun 7, 24
HC Wainwright & Co. Buy Jun 7, 24
JMP Securities Market Outperform May 24, 24
HC Wainwright & Co. Buy May 24, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Happel David President & CEO President & CEO Nov 16 Buy 2.35 590 1,386 590 11/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Sell 16 662 10,592 3,820,275 07/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Buy 16 30,000 480,000 3,850,275 07/20/23